Free tool
Diagnostics stocks
We cover 31 companies grouped under the Diagnostics theme. The median market value in the group is $1.82B. Across the group, the median move over the past trading day is −0.38%. 71% of the 31 with a 200-day average trade above it. Price change over the past year runs from −46.3% to +169.2% across the middle 80 percent of the group, with a median of +21.1%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
31 of 150 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −6.49% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −9.65% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% |
| PSNL | Personalis, Inc. | $1.82B | Small cap | +257.32% |
| OPK | OPKO Health, Inc. | $1.11B | Small cap | +6.34% |
| CSTL | Castle Biosciences, Inc. | $1.04B | Small cap | +52.96% |
| QDEL | QuidelOrtho Corporation | $1.02B | Small cap | −46.31% |
| DASA3.SA | Diagnósticos da América S.A. | $633.57M | Small cap | +93.33% |
| FLGT | Fulgent Genetics, Inc. | $545.08M | Small cap | −8.46% |
| NNNN | Anbio Biotechnology | $343.67M | Small cap | −83.55% |
| YDES | YD Bio Ltd | $307.41M | Small cap | −63.83% |
| MYGN | Myriad Genetics, Inc. | $298.43M | Small cap | −47.39% |
| BDSX | Biodesix, Inc. | $296.22M | Small cap | +225.53% |
| OSUR | OraSure Technologies, Inc. | $255.87M | Small cap | +11.08% |
| XGN | Exagen Inc. | $185.81M | Small cap | −19.69% |
| LUCD | Lucid Diagnostics Inc. | $185.35M | Small cap | −22.96% |
| IMDX | Insight Molecular Diagnostics Inc. | $145.30M | Small cap | +73.39% |
| QUCY | Quantum Cyber N.V. | $115.59M | Small cap | −15.12% |
| BNR | Burning Rock Biotech Limited | $110.10M | Small cap | +22.54% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.